JP2005341968A5 - - Google Patents

Download PDF

Info

Publication number
JP2005341968A5
JP2005341968A5 JP2005161155A JP2005161155A JP2005341968A5 JP 2005341968 A5 JP2005341968 A5 JP 2005341968A5 JP 2005161155 A JP2005161155 A JP 2005161155A JP 2005161155 A JP2005161155 A JP 2005161155A JP 2005341968 A5 JP2005341968 A5 JP 2005341968A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
seq
cell
neublastin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005161155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005341968A (ja
Filing date
Publication date
Priority claimed from US09/347,613 external-priority patent/US6593133B1/en
Application filed filed Critical
Publication of JP2005341968A publication Critical patent/JP2005341968A/ja
Publication of JP2005341968A5 publication Critical patent/JP2005341968A5/ja
Withdrawn legal-status Critical Current

Links

JP2005161155A 1998-07-06 2005-06-01 神経栄養因子 Withdrawn JP2005341968A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA199800904 1998-07-06
US9222998P 1998-07-09 1998-07-09
DKPA199801048 1998-08-19
US9777498P 1998-08-25 1998-08-25
DKPA199801265 1998-10-06
US10390898P 1998-10-13 1998-10-13
US09/347,613 US6593133B1 (en) 1998-07-06 1999-07-02 Neurotrophic factors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000558205A Division JP2002519061A (ja) 1998-07-06 1999-07-05 神経栄養因子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005326745A Division JP2006122053A (ja) 1998-07-06 2005-11-10 神経栄養因子

Publications (2)

Publication Number Publication Date
JP2005341968A JP2005341968A (ja) 2005-12-15
JP2005341968A5 true JP2005341968A5 (https=) 2006-02-02

Family

ID=27561795

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000558205A Pending JP2002519061A (ja) 1998-07-06 1999-07-05 神経栄養因子
JP2005161155A Withdrawn JP2005341968A (ja) 1998-07-06 2005-06-01 神経栄養因子
JP2005326745A Withdrawn JP2006122053A (ja) 1998-07-06 2005-11-10 神経栄養因子
JP2007120282A Withdrawn JP2007252381A (ja) 1998-07-06 2007-04-27 神経栄養因子
JP2007307603A Pending JP2008133282A (ja) 1998-07-06 2007-11-28 神経栄養因子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000558205A Pending JP2002519061A (ja) 1998-07-06 1999-07-05 神経栄養因子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2005326745A Withdrawn JP2006122053A (ja) 1998-07-06 2005-11-10 神経栄養因子
JP2007120282A Withdrawn JP2007252381A (ja) 1998-07-06 2007-04-27 神経栄養因子
JP2007307603A Pending JP2008133282A (ja) 1998-07-06 2007-11-28 神経栄養因子

Country Status (18)

Country Link
US (6) US6593133B1 (https=)
EP (2) EP1095140B1 (https=)
JP (5) JP2002519061A (https=)
KR (1) KR100743376B1 (https=)
AT (1) ATE522609T1 (https=)
AU (1) AU755114B2 (https=)
CA (1) CA2336218C (https=)
CY (1) CY1112101T1 (https=)
DK (1) DK1095140T3 (https=)
EE (1) EE05590B1 (https=)
ES (1) ES2373173T3 (https=)
HU (1) HU227870B1 (https=)
IS (1) IS2835B (https=)
NZ (1) NZ508994A (https=)
PT (1) PT1095140E (https=)
SI (1) SI1095140T1 (https=)
TR (1) TR200100056T2 (https=)
WO (1) WO2000001815A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
HK1045528B (zh) * 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
NZ526610A (en) * 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the GDNF ligand family
DK1355936T3 (da) * 2001-02-01 2007-10-29 Biogen Idec Inc Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
AU2003249013A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EA008743B1 (ru) 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
WO2004094592A2 (en) * 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US8138148B2 (en) 2005-08-16 2012-03-20 Copenhagen University GDNF derived peptides
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
WO2009002193A1 (en) * 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
RU2696481C2 (ru) 2013-10-14 2019-08-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
EP3804747A1 (en) * 2015-01-18 2021-04-14 Gloriana Therapeutics, Inc. Therapeutic protein formulations
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5284350A (en) * 1992-05-22 1994-02-08 Medical Composite Technology Foldable wheelchair and side frame assembly
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6878544B2 (en) * 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
CN1163509C (zh) 1996-05-08 2004-08-25 拜奥根有限公司 刺激神经和肾生长的RET配体(RetL)
US5754524A (en) 1996-08-30 1998-05-19 Wark; Barry J. Computerized method and system for analysis of an electrophoresis gel test
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO1998032869A1 (en) 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
HK1045528B (zh) 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
EP1115866A1 (en) * 1998-09-22 2001-07-18 University of Maryland at Baltimore Cystine knot growth factor mutants
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
PT1626058E (pt) * 1999-03-08 2008-02-15 Genentech Inc Composições e métodos para o diagnóstico de tumores
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP2001329126A (ja) 2000-05-22 2001-11-27 Bridgestone Corp 硬化性組成物
WO2002022904A1 (fr) * 2000-09-12 2002-03-21 Nkk Corporation Plaque en acier ecroui presentant une tres haute resistance a la traction et procede de production
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs

Similar Documents

Publication Publication Date Title
JP2005341968A5 (https=)
JP6946384B2 (ja) 脂質ナノ粒子を含む医薬組成物
CA2336218A1 (en) Neurotrophic factors
US11306296B2 (en) MG53 mutants, methods of making the same, and uses thereof
JPH07502404A (ja) 幹細胞阻害タンパク質
JP6230158B2 (ja) ヒトβ−ヘキソサミニダーゼＢの基質特異性を変換し、且つ、プロテアーゼ抵抗性を付与した新規高機能酵素
WO2009100934A9 (en) Identification of a novel cysteine-rich cell penetrating peptide
CA2440767A1 (en) Novel neurotrophic factors
TW202222337A (zh) 一種提高bdnf水平的方法和藥物
EP4365190A1 (en) Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof
TW202146648A (zh) 人類α-半乳糖苷酶變異體
EP2270141B1 (en) Partial peptide of lacritin
JP2003512841A5 (https=)
JP2005511015A5 (https=)
JP5678664B2 (ja) ヒトβ−ヘキソサミニダーゼＢの基質特異性を変換した新規高機能酵素
JP7847162B2 (ja) 組み換えボツリヌストキシンタイプａ軽鎖、組み換えボツリヌストキシン、並びにその組成物、その用途及びその方法
US20080102463A1 (en) Gene 4
JP2024516079A5 (https=)
US20240132865A1 (en) Pharmaceutical composition for treating, preventing or ameliorating gm1 gangliosidosis or morquio syndrome b and administration method thereof
KR102728382B1 (ko) 보툴리눔 독소의 경쇄 변이체
JP2025533863A (ja) Ｇｍ１ガングリオシド症又はモルキオ症候群ｂ型の治療、予防又は改善用薬学的組成物及びその投与方法
JP2003164290A5 (https=)
WO2024238698A2 (en) Transcription factor 4 gene editing system
KR101860103B1 (ko) 인터페론-베타 신호 펩타이드 변이체 및 이의 용도
WO2026001707A9 (zh) 一种新型透明质酸酶变体